secwatch.observer — SEC 8-K summary
======================================

Issuer:     Odyssey Therapeutics, Inc. (ODTX)
CIK:        0001882782
Form:       8-K
Filed at:   2026-08-04T11:00:16+00:00
Accession:  0001193125-26-331512
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Odyssey Therapeutics Q2 2026 net loss $52.8M; cash $433.1M; OD-001 data at UEG Week
--------------------------------------------------------------------------------

- Net loss $52.8M for Q2 2026 vs $41.2M in Q2 2025; adjusted net loss (non-GAAP) $38.4M.
- Cash, cash equivalents and marketable securities $433.1M as of June 30, 2026; expected to fund operations into 2H 2028.
- R&D expenses $36.2M (up from $30.2M); G&A $10.5M (down from $13.2M).
- OD-001 Phase 2a data accepted for oral presentation at UEG Week in October; Phase 2b monotherapy and Phase 2a combo with vedolizumab expected to initiate in 2H 2026.
- OD-002 (SLC15A4 inhibitor) CTA filing expected in 2H 2026; Phase 1/2a trial initiation in 1H 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1882782/000119312526331512/0001193125-26-331512-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1882782/000119312526331512/odtx-20260804.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-331512

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer